Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations

Haematologica

Volumn 95, Issue 10, 2010, Pages 1697-1704

  Geissinger, Eva ^a   Sadler, Petra ^a   Roth, Sabine ^a   Grieb, Tina ^a   Puppe, Bernhard ^a   Müller, Nora ^a   Reimer, Peter ^b   Vetter Kauczok, Claudia S ^a   Wenzel, Jörg ^c   Bonzheim, Irina ^d   Rüdiger, Thomas ^e   Müller Hermelink, Hans Konrad ^a   Rosenwald, Andreas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Eye Hospital   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

Author keywords

ALCL; Anaplastic large cell lymphoma; Lymphomatoid papulosis; LyP; Systemic and cutaneous CD30+ lymphoproliferations; TCR

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; ACTIVATING TRANSCRIPTION FACTOR 2; ANAPLASTIC LYMPHOMA KINASE; CD3 ANTIGEN; CD3 ANTIGEN DELTA; CD3 ANTIGEN EPSILON; CD3 ANTIGEN GAMMA; CD3 ANTIGEN ZETA; GENE PRODUCT; LAT PROTEIN; LYMPHOID ENHANCER FACTOR 1; PROTEIN BCL 10; PROTEIN C FOS; PROTEIN C JUN; PROTEIN CARMA1; PROTEIN KINASE LCK; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; PROTEIN NAFTC1; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ARTICLE; CD30+ T CELL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; LYMPHOCYTE PROLIFERATION; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; PERIPHERAL T CELL LYMPHOMA; PRIMARY CUTANEOUS LYMPHOPROLIFERATIVE DISORDER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN BIOPSY; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD3; ANTIGENS, CD30; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL, CUTANEOUS; RECEPTORS, ANTIGEN, T-CELL; TUMOR MARKERS, BIOLOGICAL;

EID: 77957763759     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.021428     Document Type: Article

References (40)

1. Bonzheim I, Geissinger E, Roth S, Zettl A, Marx A, Rosenwald A, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104(10):3358-3360.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
3. Swerdlow SH CE, Harris NL, Jaffe ES, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: Lyon: IARC Press 2008.
4. Yu JB, Blitzblau RC, Decker RH, Housman DM, Wilson LD. Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database. J Clin Oncol. 2008;26(9):1483-1488.
5. Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol. 2006;33 (Suppl 1):58-70.
6. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.
7. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007;110(7):2259-2267.
8. Hirsch B, Hummel M, Bentink S, Fouladi F, Spang R, Zollinger R, et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol. 2008;172(2):510-520.
9. Staber PB, Noehammer C, Durkop H, Schauer S, Kenner L, Linkesch W, et al. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma. Leuk Res. 2006;30(3):343-348.
10. Al-Shamkhani A. The role of CD30 in the pathogenesis of haematopoietic malignancies. Curr Opin Pharmacol. 2004;4(4):355-359.
11. Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007;282 (14):10252-10262.
12. Call ME, Wucherpfennig KW. Molecular mechanisms for the assembly of the T cell receptor-CD3 complex. Mol Immunol. 2004;40(18):1295-1305.
13. Call ME, Wucherpfennig KW. The T cell receptor: critical role of the membrane environment in receptor assembly and function. Annu Rev Immunol. 2005;23:101-125.
14. Kuhns MS, Davis MM, Garcia KC. Deconstructing the form and function of the TCR/CD3 complex. Immunity. 2006;24(2): 133-139.
15. Leiden JM. Transcriptional regulation of T cell receptor genes. Annu Rev Immunol. 1993;11:539-570.
16. Castrop J, van Wichen D, Koomans-Bitter M, van de Wetering M, de Weger R, van Dongen J, et al. The human TCF-1 gene encodes a nuclear DNA-binding protein uniquely expressed in normal and neoplastic T-lineage lymphocytes. Blood. 1995;86(8): 3050-3059.
17. Oosterwegel M, van de Wetering M, Timmerman J, Kruisbeek A, Destree O, Meijlink F, et al. Differential expression of the HMG box factors TCF-1 and LEF-1 during murine embryogenesis. Development. 1993;118(2):439-448.
18. Dorfman DM, Greisman HA, Shahsafaei A. Loss of expression of the WNT/betacatenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. Am J Pathol. 2003;162(5):1539-1544.
19. Kuo CT, Leiden JM. Transcriptional regulation of T lymphocyte development and function. Annu Rev Immunol. 1999;17:149-187.
20. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591-619.
21. Pitcher LA, van Oers NS. T-cell receptor signal transmission: who gives an ITAM? Trends Immunol. 2003;24(10):554-560.
22. Palacios EH, Weiss A. Function of the Srcfamily kinases, Lck and Fyn, in T-cell development and activation. Oncogene. 2004; 23(48):7990-8000.
23. Paterson JC, Tedoldi S, Craxton A, Jones M, Hansmann ML, Collins G, et al. The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. Haematologica. 2006;91(6): 772-780.
24. van Oers NS, Killeen N, Weiss A. Lck regulates the tyrosine phosphorylation of the T cell receptor subunits and ZAP-70 in murine thymocytes. J Exp Med. 1996;183 (3):1053-1062.
25. Samraj AK, Stroh C, Fischer U, Schulze-Osthoff K. The tyrosine kinase Lck is a positive regulator of the mitochondrial apoptosis pathway by controlling Bak expression. Oncogene. 2006;25(2):186-197.
26. Au-Yeung BB, Deindl S, Hsu LY, Palacios EH, Levin SE, Kuriyan J, et al. The structure, regulation, and function of ZAP-70. Immunol Rev. 2009;228(1):41-57.
27. Chan AC, van Oers NS, Tran A, Turka L, Law CL, Ryan JC, et al. Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol. 1994;152(10):4758-4766.
28. Canetti C, Aronoff DM, Choe M, Flamand N, Wettlaufer S, Toews GB, et al. Differential regulation by leukotrienes and calcium of Fc gamma receptor-induced phagocytosis and Syk activation in dendritic cells versus macrophages. J Leukoc Biol. 2006;79(6):1234-1241.
29. Brumbaugh KM, Binstadt BA, Billadeau DD, Schoon RA, Dick CJ, Ten RM, et al. Functional role for Syk tyrosine kinase in natural killer cell-mediated natural cytotoxicity. J Exp Med. 1997;186(12):1965-1974.
30. Chu DH, Morita CT, Weiss A. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol Rev. 1998;165:167-180.
31. Chu DH, van Oers NS, Malissen M, Harris J, Elder M, Weiss A. Pre-T cell receptor signals are responsible for the down-regulation of Syk protein tyrosine kinase expression. J Immunol. 1999;163(5):2610-2620.
32. Feldman AL, Sun DX, Law ME, Novak AJ, Attygalle AD, Thorland EC, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia. 2008;22(6):1139-1143.
33. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4(5):E131-E136.
34. Drakos E, Leventaki V, Schlette EJ, Jones D, Lin P, Medeiros LJ, et al. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders. Am J Surg Pathol. 2007;31(3):447-453.
35. Mao X, Orchard G, Russell-Jones R, Whittaker S. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas. Br J Dermatol. 2007;157(5):914-921.
36. Eckerle S, Brune V, Doring C, Tiacci E, Bohle V, Sundstrom C, et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia. 2009;23(11):2129-2138.
37. Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia. 2005;19(12):2254-2263.
38. Weil R, Israel A. Deciphering the pathway from the TCR to NF-kappaB. Cell Death Differ. 2006;13(5):826-833.
39. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
40. Schmitz R, Stanelle J, Hansmann ML, Kuppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol. 2009;4:151-174.